Cargando…

Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population

OBJECTIVES: With the approval of new non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation (NVAF), it is anticipated that their introduction may change NVAF treatment patterns; however, there is limited supporting real-world evidence. This study inves...

Descripción completa

Detalles Bibliográficos
Autores principales:	Willey, Vincent, Franchino-Elder, Jessica, Fu, An-Chen, Wang, Cheng, Sander, Stephen, Tan, Hiangkiat, Kraft, Elizabeth, Jain, Rahul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Health Services Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042605/ https://www.ncbi.nlm.nih.gov/pubmed/29961012 http://dx.doi.org/10.1136/bmjopen-2017-020676

Ejemplares similares

Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States
por: Jain, Rahul, et al.
Publicado: (2018)

Use of Telemedicine for Buprenorphine Inductions in Patients With Commercial Insurance or Medicare Advantage
por: Barsky, Benjamin A., et al.
Publicado: (2022)

Trends in Testosterone Prescriptions for Older Men Enrolled in Commercial Insurance and Medicare Advantage
por: Everhart, Alexander, et al.
Publicado: (2021)

Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation
por: Atwater, Brett D., et al.
Publicado: (2023)

Patient Perspectives on the Burden of Heart Failure with Preserved Ejection Fraction in a US Commercially Insured and Medicare Advantage Population: A Survey Study
por: Nguyen, Chi, et al.
Publicado: (2023)

Association of Health Insurance Literacy With Enrollment in Traditional Medicare, Medicare Advantage, and Plan Characteristics Within Medicare Advantage
por: Park, Sungchul, et al.
Publicado: (2022)

Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019
por: McCoy, Rozalina G., et al.
Publicado: (2021)

Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis
por: AbuDagga, Azza, et al.
Publicado: (2014)

Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease
por: Briasoulis, Alexandros, et al.
Publicado: (2018)

Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort study
por: Jeffery, Molly Moore, et al.
Publicado: (2018)

Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009
por: Dalal, Anand A, et al.
Publicado: (2011)

Newer Anticoagulants for Non-Valvular Atrial Fibrillation
por: Harburger, Joseph M., et al.
Publicado: (2012)

Trajectories of Oral Anticoagulation Adherence Among Medicare Beneficiaries Newly Diagnosed With Atrial Fibrillation
por: Hernandez, Inmaculada, et al.
Publicado: (2019)

Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers
por: Lin, Dora H., et al.
Publicado: (2018)

Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation
por: da Silva, Rose M.F.L.
Publicado: (2014)

Patterns of Comorbidity and Multimorbidity Among Patients With Multiple Sclerosis in a Large US Commercially Insured and Medicare Advantage Population
por: Dai, Dingwei, et al.
Publicado: (2022)

PO-05-187 DOES COVID-19 INCREASE THE RISK OF ATRIAL FIBRILLATION? A RETROSPECTIVE ANALYSIS OF A LARGE ADMINISTRATIVE CLAIMS DATABASE OF COMMERCIALLY INSURED NON-ELDERLY AND MEDICARE ADVANTAGE BENEFICIARIES IN THE UNITED STATES.
por: Berman, Adam E., et al.
Publicado: (2023)

Compared to commercially insured patients, Medicare advantage patients adopt newer diabetes drugs more slowly and adhere to them less
por: Flory, James H, et al.
Publicado: (2021)

Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA
por: Dhamane, Amol D, et al.
Publicado: (2021)

Multimorbidity and Its Associations With Anxiety and Depression Among Newly Diagnosed Patients With Breast Cancer: A Retrospective Observational Cohort Study in a US Commercially Insured and Medicare Advantage Population
por: Dai, Dingwei, et al.
Publicado: (2022)

Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population
por: Amin, Alpesh, et al.
Publicado: (2019)

588. Retrospective Analysis of Clinical Characteristics and Treatment Patterns Among HIV Patients with Commercial and Medicare Advantage Health Insurance in the United States
por: Priest, Julie, et al.
Publicado: (2018)

Comparison of Ambulatory Care Access and Quality for Beneficiaries With Disabilities Covered by Medicare Advantage vs Traditional Medicare Insurance
por: Johnston, Kenton J., et al.
Publicado: (2022)

Evaluation of Potentially Avoidable Acute Care Utilization Among Patients Insured by Medicare Advantage vs Traditional Medicare
por: Beckman, Adam L., et al.
Publicado: (2023)

Risk Stratification and Anticoagulation in Low-risk Non-valvular Atrial Fibrillation
por: Arya, Arash
Publicado: (2013)

Anticoagulation Therapy for Non-valvular Atrial Fibrillation: A Mini-Review
por: Wu, Jia, et al.
Publicado: (2020)

Anticoagulant Prescribing for Non‐Valvular Atrial Fibrillation in the Veterans Health Administration
por: Rose, Adam J., et al.
Publicado: (2019)

Balancing the benefits and harms of oral anticoagulation in non-valvular atrial fibrillation
por: Lindley, Richard I
Publicado: (2021)

Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation
por: Calderon, Jose Miguel, et al.
Publicado: (2022)

Metabolomic and Proteomic Analyses of Persistent Valvular Atrial Fibrillation and Non-Valvular Atrial Fibrillation
por: Hu, Bo, et al.
Publicado: (2021)

How Do the Hospital Prices Paid by Medicare Advantage Plans and Commercial Plans Compare With Medicare Fee-for-Service Prices?
por: Maeda, Jared Lane K., et al.
Publicado: (2018)

Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions
por: Di Biase, Luigi
Publicado: (2016)

Use of Anticoagulants in Patients With Non-Valvular Atrial Fibrillation Who Are at Risk of Falls
por: Shanah, Layla, et al.
Publicado: (2020)

Factors Associated with Anticoagulation Adherence in Chinese Patients with Non-Valvular Atrial Fibrillation
por: Song, Ting, et al.
Publicado: (2021)

Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US
por: Sandhaus, Robert, et al.
Publicado: (2020)

The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States
por: Sacks, Naomi C., et al.
Publicado: (2022)

Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance
por: Johnson, Kate M., et al.
Publicado: (2022)

Anticoagulant Use, the Prevalence of Bridging, and Relation to Length of Stay among Hospitalized Patients with Non-Valvular Atrial Fibrillation
por: Smoyer-Tomic, Karen, et al.
Publicado: (2012)

Increasing Trends in the Use of Hospital Observation Services for Older Medicare Advantage and Privately Insured Patients
por: Lind, Keith D., et al.
Publicado: (2017)

Can Insurance Market Competition Coexist With Provider Price Regulation? Evidence From Medicare Advantage
por: Berenson, Robert A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ng1fcghe1qpff15ta4ahu32i4j